Loading stock…

Zimmer Biomet Holdings, Inc. (ZBH) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated today

Zimmer Biomet Holdings, Inc.

ZBHMarket cap $17BPrice $88.9

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Equipment

Makes artificial knees, hips, and surgical robots that help millions walk again after joint replacement. One of the world's largest orthopedic device makers, its implants are inside roughly a million patients every year.

In Bastion Portfolios?

52W Return-12%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+6%5

Revenue Forecast

Rev CAGR (1y)+4%4

Rev CAGR (3y)+4%3

Rev CAGR (5y)+4%3

Earnings Forecast

EPS Growth Y+1+143%10

EPS Growth Y+2+5%5

EPS Growth Y+3+7%6

Quality

Margins

EBIT Margin17%7

Net Income Margin9%5

Free Cash Flow Margin14%7

Debt

Net Debt/EBITDA2.83

Efficiency

ROE6%3

ROA4%5

Earnings Stability55

GEAR+AVERAGE47

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)108

P/E Ratio (Forward 3y)98

P/BV1.38

EV Multiples

EV/EBITDA Fwd97

EV/EBIT Fwd108

Yield

Free Cash Flow Yield7.1%8

Dividend Yield1.1%3

Momentum

Short term

1 month return-6%4

3 month return-0%6

YTD return-0%5

Mid term

Price vs 52wHigh84%6

1 year return-8%4

Long term

3 year return-17%2

5 year return-35%2

Risk Shield

Price Risk

Beta0.48

Volatility33%6

Free Cash Flow

Free Cash Flow Margin14%7

Free Cash Flow Yield7.1%8

Quality

ROCE7%4

Earnings Stability55

Net Debt/EBITDA2.83

02Growth

Is it actually growing, and how fast?

ZBHZimmer Biomet Holdings

Revenue FY25$8.2B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+143%10

EPS growth, FY27E+5%5

EPS growth, FY28E+7%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 7%/yr vs revenue 4%/yr).

WATCH

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 4%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-0%6

YTD return-0%5

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return-8%4

3-year return-17%2

5-year return-35%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 8% over the past year, now 16% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-6%), over three months (+0%) and so far this year (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-17% over three years and -35% over five), behind 80% of the market.

BOTTOM LINE

Falling Knife

Returns rank poorly over both the short and long run, and the price is still falling. Momentum is firmly negative — catching this is a bet against the tape, not with it. Wait for a base to form. The one thing to watch: the multi-year record is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Zimmer. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

ZBHZimmer Biomet Holdings

Revenue FY25$8.2B

GROWTH RATING↗

WEAK29 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+6%5

Revenue, next 1Y+4%4

Revenue, next 3Y, CAGR+4%3

Revenue, next 5Y, CAGR+4%3

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+143%10

EPS growth, FY27E+5%5

EPS growth, FY28E+7%6

GROWTH ASSESSMENT

STRENGTHS

Earnings are set to grow in step with sales (EPS about 7%/yr vs revenue 4%/yr).

WATCH

Revenue grew 6%/yr over the last 3 years and is set to keep growing around 4%/yr.

WEAKNESSES

Growth is the weak spot here, trailing 71% of companies worldwide.

Revenue is set to grow 4%/yr over the next 3 years, behind most of the market.3/10

Over five years revenue is set to grow 4%/yr, behind 70% of companies worldwide.3/10

BOTTOM LINE

Margin Expander

Growth is a weak point here. The one thing to watch: forward revenue growth trails the market.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

WEAK26 / 100

SHORT-TERM RETURNS▾SCORE

1-month return-6%4

3-month return-0%6

YTD return-0%5

MID & LONG-TERM▾SCORE

% of 52-week high84%6

1-year return-8%4

3-year return-17%2

5-year return-35%2

MOMENTUM ASSESSMENT

STRENGTHS

None flagged.

WATCH

It's down 8% over the past year, now 16% below its 52-week high. That is right in line with the market.

Returns sit at the market level over the past month (-6%), over three months (+0%) and so far this year (+0%).

WEAKNESSES

Weak long-term results. It has been a disappointing long-term hold (-17% over three years and -35% over five), behind 80% of the market.

BOTTOM LINE

Falling Knife

04Value

Are you paying a fair price for it?

Stop guessing on Zimmer. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community